IP 2026 Release: 121 New Monographs, Global Recognition & First-Time Blood Standards

The Indian Pharmacopoeia 2026 (IP 2026) is the 10th edition of India’s official compendium of drug quality standards — recently released by the Union Health Minister. This version represents a major advancement in India’s pharmaceutical regulatory framework, incorporating 121 new drug monographs and expanding total standards to 3,340 authoritative entries.

In this video, we cover:
🔹 Overview of IP 2026: Purpose and regulatory significance
🔹 New Monographs Added: Key therapeutic categories including anti-tubercular, anti-diabetic, anti-cancer medicines, and iron supplements — strengthening coverage of medicines used in national health programmes.
🔹 First-Time Inclusion of Blood Component Standards: Standards for transfusion medicine aligned with updated Drugs & Cosmetics rules.
🔹 Pharmacovigilance Highlights: India’s rising global ranking in WHO pharmacovigilance contributions reflects enhanced patient safety reporting and regulatory vigilance.
🔹 International Recognition: IP 2026 standards now recognised in multiple countries of the Global South, reinforcing global confidence in Indian pharmaceutical quality.

Whether you are a pharmacist, student, regulator or industry professional, this guide provides concise insight into what the 2026 edition means for drug quality, manufacturing compliance, and regulatory practice.

👉 Don’t forget to Like, Subscribe, and Comment your questions or requests for more detailed breakdowns of specific monographs or regulatory changes.

📌 Follow for more updates on pharmacy education, regulatory standards, and industry insights.

Видео IP 2026 Release: 121 New Monographs, Global Recognition & First-Time Blood Standards канала PHARMACY WITH SHUBHAM